Anal Fissure Treatment Market Report Global Business Insights 2019 – By Trends,

Posted by Apeksha on July 9th, 2021

Global Anal Fissure Treatment Market Research Report: Information, by Treatment Type (Medication and Surgery), Route of Administration (Oral and Topical), End User (Hospitals & Clinics and Research & Academic institutes) and Region (North America, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

Overview:

The global Anal Fissure Treatment Market Report is expected to rise and touch a valuation of USD 2,526.5 million by 2023, at a 7.6% CAGR during the forecast period (2018-2023). Anal fissures are small tears near the mucosal lining of the anus. Deeper cuts may take a combination of oral and topical medicine to alleviate the pain.

Regional Analysis:

Americas accounted for 39.1% market share in 2017, followed by Europe (26.7%) and APAC (20%). The Americas are predicted to touch a valuation of USD 1,000.6 million by 2023 at a CAGR of 7.8% over the forecast period. This can be credited to rising number of cases of inflammatory bowel disease among the American populace.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/anal-fissure-treatment-market-3841

Competitive Analysis:

Major names operational in the anal fissure treatment market are AstraZeneca (U.K.), Abbott Laboratories (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline Plc (U.K.), Eisai Co. Ltd. (Japan), Cigna (U.S.), Bayer AG (Germany), Taro Pharmaceutical Industries Ltd. (Israel), Allergan Inc. (U.S.), Valeant Pharmaceuticals International Inc (Canada), Teva Pharmaceutical Industries Ltd. (Israel), and Cook (U.S.).

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com